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A B S T R A C T
Until now the prebiotic potential of pure trisaccharide raffinose on human health assessed through high-
throughput sequencing remains poorly investigated. In this work, an in vitro model using human fecal inocula of
two healthy volunteers (D1 and D2) was used to study the prebiotic potential of raffinose and compare it with
the well-stablished and commercial prebiotic lactulose. The intestinal microbiota showed preference for raffi-
nose as substrate showing the highest consumption value at 48 h (96.0 ± 0.9% D1 and 95.3 ± 0.7% D2). The
fermentation of raffinose decreased the medium pH, the ammonia concentration and the relative amount of
Proteobacteria, while increasing the total production of lactate and short chain fatty acids (129.9 ± 2.6 mmol/L
D1 and 179.6 ± 0.6 mmol/L D2), CO2 (10.8 ± 0.8 mmol/Lmedium D1 and 5.2 ± 0.3 mmol/Lmedium D2) and
the relative amount of Bifidobacterium and Lactobacillus. This study suggests that raffinose holds potential
functional properties for human health.
1. Introduction
The loss of food functional properties due to the current industrial
processing and the growing changes on people modern lifestyles asso-
ciated with unhealthy eating behaviors are among the negative con-
sequences of the globalization impact (Adamberg et al., 2014). As a
result, the global epidemic of diet-related diseases had become a major
public health issue (WHO - World Health Organization, 2018). How-
ever, the consumer awareness has increased towards the importance of
using food as preventive medication, being willing to pay more for
healthier eating options (Forbes, 2015). Thus, bioactive compounds
produced from a natural source are currently preferred to modern
therapeutic agents (Samanta et al., 2015). In particular, the use of
bioactive compounds, such as prebiotics, has been shown to be very
attractive given their role on modulating the gut microbiota and the
subsequent beneficial effects on human and animal health over dif-
ferent physiological functions. The link between gut microbiota health
and several different disorders, e.g. disbyosis caused by antibiotics in-
take or food poisoning, has been the recent focus of increased research
(Kang et al., 2019; Yeung, Mocan, & Atanasov, 2018).
Recently updated by the International Scientific Association for
Probiotics and Prebiotics (ISAPP), the current definition establishes a
prebiotic as “a substrate that is selectively utilized by host
microorganisms conferring a health benefit”, and the host can be either
human or animal (Gibson et al., 2017). Prebiotic beneficial effects have
been reported on the gastrointestinal tract, cardiometabolism, skeletal
system, nervous system, among others (Gibson et al., 2017; Saad,
Delattre, Urdaci, Schmitter, & Bressollier, 2013).
The global market demand of prebiotic is in expansion, registering
623.5 kton in 2015 and growing at a compound annual growth rate of
8.0% from 2016 to 2024 (Grand View Research, 2018). Prebiotic car-
bohydrates, particularly oligosaccharides, are the most widely studied
and the best market established type of prebiotics. These compounds
are also marketed beyond their traditional functional properties, being
industrially used for instance as sugar and fat replacement, as well as
taste and texture enhancement (Das, Choudhary, & Thompson-Witrick,
2019; Saremnezhad, Zargarchi, & Kalantari, 2020). Prebiotic oligo-
saccharides present favorable organoleptic properties, temperature and
acidic stability which make them potential food ingredients (Zhao et al.,
2017).
However, new potential prebiotic and less explored oligosacchar-
ides have emerged as possible competitors, namely raffinose. Raffinose
is an oligosaccharide composed by galactose, glucose, and fructose re-
sidues that can be hydrolyzed to D-galactose and sucrose by the enzyme
α-galactosidase (α-GAL) (Tester & Karkalas, 2003). This trisaccharide is
non-digestible to humans but can be metabolized by colon bacteria
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(Fernando et al., 2010), therefore being considered a prebiotic candi-
date. Furthermore, raffinose can be produced from cheap and abundant
agro-residues such as soybean waste, holding a promising environ-
mental and economic advantage.
Prebiotic oligosaccharides are used by the gut microbiota to growth
and to produce short-chain fatty acids (SCFAs), lactate (a known pre-
cursor of SCFAs) (Flint, Duncan, Scott, & Louis, 2015), gases (mostly
carbon dioxide and hydrogen), among other products (Topping &
Clifton, 2001). The most common SCFAs being produced are acetate,
propionate and butyrate, widely reported as key metabolites for in-
testinal health, benefiting also other body sites than the gut (Gibson
et al., 2017).
Different approaches for testing the prebiotic potential of new
compounds have been described. However, an in vitro model is con-
sidered a more suitable first-stage strategy to screen prebiotics candi-
dates (Date et al., 2014), contrarily to in vivo studies which are ex-
pensive and time-consuming.
In agreement with the recent International Scientific Association for
Probiotics and Prebiotics (ISAPP) guidelines, the in vitro models should
include the use of fecal inocula and accurate high-throughput sequen-
cing techniques to evaluate the microbial modulation. The prebiotic
potential of the raffinose family of oligosaccharides has been reported
using single or co-cultured microorganisms' models (Martínez-
Villaluenga, Frías, Vidal-Valverde & Gómez, 2005; Ose et al., 2018).
Nonetheless, in the light of ISAPP guidelines, these approaches cannot
mimic the complex diversity of the intestinal microbiota (Gibson et al.,
2017). Up to now, studies regarding the prebiotic effect of pure tri-
saccharide raffinose meeting the ISAPP requirements are scarcely re-
ported. In this study, an in vitro batch culture model was used to
evaluate the prebiotic potential of raffinose and compare it with com-
mercial lactulose, using human fecal inocula of two adult healthy do-
nors. Among the most widely studied and commercialized prebiotics,
lactulose presents a chemical structure that better resembles raffinose,
therefore comprising an interesting comparison model. Next generation
sequencing techniques, namely Illumina MiSeq analysis was used to
evaluate microbiota diversity. To the authors’ knowledge, this is the
first study exploring the prebiotic potential of trisaccharide raffinose,
used as a pure substrate and evaluated under an experimental approach
compatible with the ISAPP guidelines.
2. Experimental
2.1. Materials
All chemicals and media components used were of analytical grade
and purchased from Sigma-Aldrich (St. Louis, MO), including com-
mercial raffinose, unless specified otherwise.
2.2. Fecal inoculum
Fecal samples were collected from two healthy human volunteers
(Donor 1, coded D1 and donor 2, coded D2), both aged 26, who were on
a non-specific Mediterranean diet, had no metabolic and gastro-
intestinal diseases, were non-smokers and had not received any anti-
biotics, pre- or probiotic supplements for at least 3 months before the
fecal donation. A voluntary informed consent was obtained from the
two fecal donors prior to this study. The fecal samples were 1:10 (w/w)
diluted in anaerobic phosphate-buffered saline (0.1 M) at pH 7.0 and
stored at 4 °C overnight before the inoculation. The anaerobic condi-
tions were maintained using 100% N2 in the headspace.
2.3. In vitro fermentation of raffinose
Fermentation experiments were performed using an in vitro static
batch culture model, as described by Amorim et al. (2020). Briefly, the
fermentations were run in anaerobic conditions at 37 °C for 48 h. The
growth medium at pH 7.0 was composed of: peptone water (2 g/L),
yeast extract (2 g/L), NaCl (0.1 g/L), KH2PO4 (40 mg/L), K2HPO4
(40 mg/L), MgSO4.7H2O (0.01 g/L), NaHCO3 (2 g/L), CaCl2.6H2O
(0.01 g/L), Tween 80 (14.8 ml/L), bile salts (0.5 g/L), hemin (5 mg/L),
cysteine HCl (0.5 g/L), vitamin K1 (74.1 μl/L), Na2S.9H2O (0.8 mmol/
L) and resazurine (1 mg/L). The raffinose solution was added at a final
concentration of 10 g/L, when required.
The vitamin k1 and substrate solutions were filter-sterilized and
added to the remaining medium components sterilized by autoclave at
121 °C during 20 min. The fecal inoculum was added to the growth
medium at 11% (v/v). The anaerobic conditions were attained by
pressurizing the bottles headspace with N2 up to 170 KPa.
Samples of the headspace and the fermentation broth were collected
at different time points. The latter were centrifuged at 4000 x g for
10 min and the supernatant was collected and stored at −20 °C for
further analysis. At 48 h the final pH of the medium was measured and
the biomass samples were centrifuged, washed and resuspended in PBS
(0.1 M, pH 7.0), and stored at −20 °C for DNA isolation and further
sequencing analysis. Fermentations assays were performed in duplicate,
running a negative control as blank with no prebiotic addition.
2.4. Analytical techniques
The substrate consumption and the production of lactate and SCFAs
were analyzed by high performance chromatography (HPLC) according
to Amorim et al. (2020). The headspace samples were evaluated by gas
chromatography (GC) as described by Arantes, Alves, Alfons, Alves, and
Sousa (2017).
2.5. Microbial analysis
Liquid samples from fecal inocula and fermentation broth (48 h)
were taken and used for DNA extraction using the FastDNA SPIN kit for
soil (MP Biomedicals, Solon, OH), according to the manufacturer's
procedures. The extracted DNA samples were further submitted to high-
throughput sequencing (16S rRNA gene) by Illumina MiSeq technology,
as described in detail previously (Salvador et al., 2019). All the se-
quencing analysis were performed at RTL Genomics (Lubbock, TX) and
all the samples were analyzed in duplicate. All the sequences were
submitted as FASTQ files at the European Nucleotide Archive under the
accession number: ERS3592391, ERS3592398, ERS3592399 and
ERS3592411 (BioProject accession number: PRJEB33616).
2.6. Data analysis
The negative (blank) and the positive (lactulose) controls reported
previously by the same authors (Amorim et al., 2020) were used in this
study for comparison purposes. Paired and unpaired t-tests were per-
formed when required. Significant differences were considered when p-
value was<0.05.
3. Results and discussion
3.1. Substrate intake and production of lactate and short-chain fatty acids
(SCFAs)
The total production of lactate and SCFAs (acetate, propionate and
butyrate), and the residual substrate present in the fermentation
medium are shown in Fig. 1. The fermentation of lactulose and raffinose
at 10 g/L increased significantly the total amount of lactate and SCFAs
(t-test student, α = 0.05) for both donors, as consequence of the se-
lective growth-stimulation of SCFAs-producing bacteria (detailed in
section 3.4). The results presented in Fig. 1 are in accordance with
previous evaluations of the prebiotic effect reported for lactulose, using
human fecal inocula (Ito et al., 1997), and raffinose using single cul-
tures of intestinal bacteria (Ose et al., 2018).
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The maximum production of lactate and SCFAs was achieved at 24 h
for the blank (49.7 ± 1.3 mmol/L D1, and 47.0 ± 1.3 mmol/L D2)
and between 36 and 48 h for both lactulose (131.2 ± 1.7 mmol/L D1
and 113.6 ± 0.9 mmol/L D2) and raffinose (129.9 ± 2.6 mmol/L D1
and 179.6 ± 0.6 mmol/L D2). At this time point, the highest substrate
consumption was found (lactulose: 80.5 ± 3.6% D1 and 72.9 ± 1.2%
D2; raffinose: 95.3 ± 0.7% D1 and 96.0 ± 0.9% D2).
Raffinose was mainly consumed during the first 24 h of fermenta-
tion (64.5 ± 1.2 0.8% D1 and 79.8 ± 0.7% D2), leading to the faster
accumulation of lactate and SCFAs (114.9 ± 4.0 mmol/L D1 and
148.2 ± 2.9 mmol/L D2) (Fig. 1). Additionally, when a 10 g/L mixture
of lactulose and raffinose (1:1) was fermented by the fecal inocula of
both donors, raffinose was firstly consumed, thus corroborating the
preference of fecal microbiota for this substrate (data not shown).
Interestingly, for D2 the total amount of SCFAs and lactate obtained
at 48 h with raffinose was 1.4-fold higher when compared with lactu-
lose, while D1 presented no significant differences. This difference may
be related with the specific microbiota diversity of each donor in-
oculum (Table A.1, Appendix A). Adamberg et al. (2018) also reported
that fecal microbiota of normal and overweight children exhibited
different compositions that responded in specific manners to
oligosaccharides and polysaccharides. Particularly, lactic acid was the
main fermentation product for overweight children inocula, while the
inocula of normal weight children resulted mostly on the production of
acetate and butyrate. These facts highlight the need of testing a larger
and more representative sample size of donors, including volunteers
from different age, culture, health backgrounds and dietary habits,
among others.
Besides the total production of SCFAs, the specific profile produc-
tion, i.e. the proportions in which each SCFA is being produced, is also
essential to evaluate the potential benefits on the host health related
with the intake of these prebiotics (Gibson et al., 2017).
Fig. 2 shows the respective production profiles of lactate, acetate,
propionate and butyrate, obtained at 48 h of fermentation, using
human fecal inocula from D1 and D2.
Overall, acetate was the main SCFAs accumulated at 48 h (D1:
37.4 ± 0.7 mmol/L blank, 77.5 ± 0.6 mmol/L lactulose and
73.6 ± 1.4 mmol/L rafinose; D2: 30.2 ± 0.9 blank, 81.0 ± 0.7
lactulose and 119.1 ± 0.1 rafinose), with raffinose presenting the
highest production of this metabolite that has been reported as playing
an important role on colorectal cancer prevention (Casanova, Azevedo-
Silva, Rodrigues, & Preto, 2018; Ferro et al., 2016; Oliveira et al.,
2015).
On the other hand, lactate was the second most generated meta-
bolite and it was only produced in the presence of a prebiotic substrate,
with raffinose presenting the highest values (38.3 ± 0.5 mmol/L D1
and 37.8 ± 0.2 mmol/L D2). These results suggest that both raffinose
and lactulose may stimulate the growth of lactate-producing bacteria.
Lactate is a known precursor of SCFAs ant it has been reported as
holding bioactive properties on human health, namely by being able to
regulate critical functions of macrophages and dendritic cells of the
immune system and to modulate inflammatory activation of epithelial
cells (Garrote, Abraham, & Rumbo, 2015). Moreover, lactate and lac-
tate-producing bacteria may exert an effect on extra-intestinal sites,
such as vagina representing a key line defense against vaginal patho-
gens (Amabebe & Anumba, 2018). Thus, raffinose presents potential to
be applied on prebiotic formulations for vaginal infections.
Ito et al. (1997) and Ose et al. (2018) also reported acetate and
lactate as the most abundant SCFA resulting from the fermentation of
lactulose and raffinose using fecal inocula and mono-culture models,
Fig. 1. Total production of lactate and short chain fatty acids (SCFAs) (A) and
conversion of lactulose or raffinose (B) supplemented at a starting concentra-
tion of 10 g/L. The fermentations were run during 48 h, using human fecal
inocula from donors D1 and D2. A negative control was performed in the ab-
sence of prebiotics (blank): Blank D1 ( ); Blank D2 ( ); Lactulose
D1 ( ); Lactulose D2 ( ; Raffinose D1 ( ); Raffinose D2
( ). Results represent the average of two independent fermentations and
the analysis of each sample in triplicate ± standard deviation.
Fig. 2. Production profile of lactate and short chain fatty acids obtained after
48 h of fermentation, using human fecal inocula from donors D1 and D2. The
medium was supplemented with lactulose or raffinose at a starting concentra-
tion of 10 g/L. A negative control was performed in the absence of prebiotics
(blank): Lactate ( ); Acetate ( ); Proprionate ( ); Butyrate (
). Results represent the average of two independent fermentations and the
analysis of each sample in triplicate ± standard deviation.
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respectively.
The supplementation of lactulose or raffinose did not increase the
production of butyrate. However, since lactate is an intermediary of
other SCFAs, it would be possible that by increasing the fermentation
time, a decrease of this metabolite and subsequent accumulation of
SCFAs would be observed. Moreover, Bothe et al. (2017) reported a
dose-dependent prebiotic effect of lactulose, which influenced the
production of butyrate, using a computer-controlled in vitro model of
the human large intestine. This highlights the importance of estab-
lishing the most effective prebiotic dose through the use of in vivo
models.
3.2. Variation of pH and ammonia concentration
The increased production of SCFA due to the prebiotic fermentation
causes a pH drop, which in turn promotes the reduction of intestinal
pathogenic agents and ammonia production that is related with bad
fecal odor and colon carcinogenesis (Visek, 1978).
The pH and the ammonia concentration values obtained after 48 h
of fermentation are presented in Table 1. As expected, the supple-
mentation with lactulose and raffinose led to an equivalent pH and
ammonia reduction. Adamberg et al. (2018) also reported a reduction
of the final pH values from 7.3 to 7.4 (control cultures) to pH 5.1 and
5.3 (cultures supplemented with a mixture of raffinose and melibiose).
Compared with in vivo and human studies, the in vitro models
present some limitations, since they cannot replicate all the complex
conditions occurring in the colon (Poeker et al., 2018). For instance, in
an in vitro model without pH control, the fermentation medium mimics
the distal colon pH at baseline. Nonetheless, the SCFAs formed during
the fermentation are not absorbed, as it occurs using an in vivo model,
thus, these metabolites cause significant variations of the medium pH
(Pham & Mohajeri, 2018), which is a limitation of this type of models.
On the other hand, the rapid absorption of SCFAs in in vivo models
limits their measurement (Carlson, Erickson, Hess, Gould, & Slavin,
2017). Therefore, the in vitro models are an attractive alternative tool to
study the kinetics of colonic fermentation (Tsitko, Mattila, Maukonen,
& Saarela, 2019), but they should be regarded as semi-representative
models of colonic fermentation.
3.3. Production of H2 and CO2
The prebiotic fermentation by human fecal inocula also exerts an
effect on the production of gases. For both donors (D1 and D2), the
addition of raffinose increased significantly the production of CO2 when
compared with the blank in particular for D1 (Fig. 3). The maximum
production of CO2 obtained with raffinose was 10.8 ± 0.8 mmol/
Lmedium at 48 h (D1) and 5.2 ± 0.3 mmol/Lmedium at 36 h (D2).
Production of methane was not detected, which may suggest the
absence of methanogenic bacteria in the original microbiota. In fact, it
is known that only a fraction of the human population harbor metha-
nogenic bacteria on their gut microbiota (Ghoddusi, Grandison,
Grandison, & Tuohy, 2007). However, the DNA profiles of the fer-
mentation samples must be analyzed to support this hypothesis as
further described in section 3.4.
Excessive production of gas resulting from raffinose fermentation
may cause bloating and flatulence problems, which represents a clinical
disincentive to its use (Cummings, Macfarlane, & Englyst, 2001). Dahl,
Hanifi, Zello, and Tyler (2014) reported a slight increase of the flatu-
lence and bloating rate due to the daily consumption of 5 g of raffinose
by healthy adults, but no differences were found for diarrhea or ab-
dominal pain when compared with the control. Suarez et al. (1999)
verified an increase of the flatus rate in human subjects caused by the
ingestion of 80 g of different soybean flours derived from beans. In
particular, the flour containing higher amounts of raffinose (0.51%)
resulted in the highest flatus rate. Therefore, it is essential to determine
the proper dose of raffinose intake through in vivo models, consisting in
the recommended dose that maximizes the prebiotic effect, while pre-
senting minimal secondary effects.
3.4. Effect of prebiotics fermentation on intestinal microbiota
The microbiota analysis of the fecal inocula showed the
Table 1
pH and concentration of ammonia in the fermentation broth after 48 h of
human fecal inocula growth from donors D1 and D2. The absence of prebiotics
(blank) and the supplementation of lactulose or raffinose at 10 g/L were stu-
died. Results represent the average of two independent fermentations and the






Blank 7.08 ± 0.02 152 ± 7 7.00 ± 0.03 162 ± 5
Lactulose 3.56 ± 0.03 59 ± 1 3.585 ± 0.05 49 ± 3
Raffinose 3.502 ± 0.002 49 ± 6 3.605 ± 0.005 42 ± 2
Fig. 3. Production of H2 and CO2 by human fecal inocula from donors D1 (A)
and D2 (B) during 48 h. The absence of prebiotics (blank) and the supple-
mentation of lactulose or raffinose at 10 g/L were studied: Blank H2 ( );
Blank CO2 ( ); Lactulose H2 ( ); Lactulose CO2 ( );
Raffinose H2 ( ); Raffinose CO2 ( ). Results represent the average
of two independent fermentations and the analysis of each sample in tripli-
cate ± standard deviation.
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characteristic gut microbiota diversity of healthy human adults
(Eckburg et al., 2005), including the presence of six bacterial phyla, of
which Firmicutes dominate in terms of relative abundance, Table A.1,
Appendix A.
The medium supplementation with lactulose or raffinose resulted in
a similar modulation of the gut microbiota of both donors after 48 h of
fermentation, Fig. 4 and Fig. 5. When compared with the blank, both
prebiotics increased the relative abundance of well-known probiotics,
namely organisms belonging to Bifidobacteria and Lactobacillus, with
raffinose showing a 1.8 ± 0.8- and 4.1 ± 0.1-fold increase of Bifi-
dobacteria and 725 ± 45- and 750± 0-fold increase of Lactobacillus for
donors 1 and 2, respectively.
However, after the fermentation of lactulose or raffinose, micro-
organisms belonging to the order Lactobacillales presented the highest
relative abundance for D1, while Bifidobacteriales dominated in D2.
Those differences could be explained by the intrinsic variations on the
original inocula of the donors. Therefore, the specific prebiotic effect
will greatly depend on the original inocula of the donors, although the
main pattern of bacterial growth generated by the prebiotic fermenta-
tion were comparable between them. This fact highlights, as previously
mentioned, the importance of performing in vitro and in vivo studies
with a representative sample, in terms of size and diversity of subjects.
Lactobacillus and Bifidobacterium are widely known probiotic able to
use complex carbohydrates and to mainly produce acetate and lactate,
releasing CO2, which corroborates the results presented in sections 3.1
and 3.2. However, these bacteria may also stimulate butyrate-produ-
cing microorganisms in case of cross-feeding effect, resulting in the
production of this SCFA (Gibson et al., 2017).
Fig. 4. Relative abundance of different bacteria after 48h of in vitro fermentation by fecal inocula from donor1 in the absence of prebiotics (blank) (A) or enriched
with a prebiotic solution of lactulose (B) or raffinose (C) at 10 g/L.
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On the other hand, a significant reduction of relative amount of
Proteobacteria was observed due to the fermentation of prebiotics. The
highest reduction was achieved for raffinose (53 ± 7-fold D1, 43 ± 8-
fold D2).
The abundance of Proteobacteria on gut microbiota is associated to
several intestinal diseases. This phylum comprises several known
human pathogens (Rizzatti, Lopetuso, Gibiino, Binda, & Gasbarrini,
2017), including Escherichia coli whose relative abundance was sig-
nificantly reduced by de addition of lactulose (32.0± 5-fold D1,
1350 ± 650-fold D2) and raffinose (12±4-fold D1, 28±8-fold D2)
(Table A.1, Appendix A). The reduction in the ammonia concentration
(section 3.3) was confirmed by the reduction of ammonia producing
bacteria including E. coli and Clostridium sp.
The absence of methanogenic archaea on the original inoculum of
D1 could explain the lack of CH4 production (Table A.1, Appendix A).
However, D2 presents Methanobacteriacea members on its original
inoculum (0.85 ± 0.15%) which in turn decreased with the
fermentation of lactulose and raffinose, with raffinose presenting the
most significant reduction (25±5-fold). Nevertheless, the production
of CH4 from D2 inoculum could be below the sensitivity limit of the GC
method, since the relative abundance of these bacteria was significantly
low on both inoculum and blank samples.
Taking into account the results herein gathered, raffinose presents a
high prebiotic potential, comparable to the well-accepted lactulose,
specially to act on Bifidobacterium and Lactobacillus reduced dysbiosis.
4. Conclusions
The addition of trisaccharide raffinose increased the production of
SCFAs and CO2, reducing the final pH of the medium and the ammonia
concentration. Moreover, the presence of raffinose as substrate in-
creased the relative abundance of Bifidobacterium and Lactobacillus
species, while reducing Proteobacteria, including widely known patho-
gens, such as E. coli.
Fig. 5. Relative abundance of different bacteria after 48h of in vitro fermentation by fecal inocula from donor 2 in the absence of prebiotics (blank) (A) or enriched
with a prebiotic solution of lactulose (B) or raffinose (C) at 10 g/L.
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This study strongly suggests that raffinose holds potential prebiotic
properties for human health and, subsequently, potential to be com-
mercialized as functional food ingredient. Nevertheless, in vivo studies
should be further carried out to access its prebiotic effect in a more
realistic model and to establish a more accurate recommended daily
dose of this compound.
CRediT authorship contribution statement
Cláudia Amorim: Investigation, Methodology, Writing - original
draft. Sara C. Silvério: Investigation, Methodology, Writing - review &
editing. Beatriz B. Cardoso: Investigation, Methodology. Joana I.
Alves: Investigation, Methodology, Writing - review & editing. Maria
Alcina Pereira: Funding acquisition, Resources, Validation, Writing -
review & editing. Lígia R. Rodrigues: Funding acquisition, Resources,
Validation, Supervision, Writing - review & editing, Project adminis-
tration.
Declaration of competing interest
None.
Acknowledgments
CA an BBC acknowledge her grants (UMINHO/BPD/4/2019 and
SFRH/BD/132324/2017) from Portuguese Foundation for Science and
Technology (FCT). The study received financial support from FCT under
the scope of the strategic funding of UID/BIO/04469/2020 unit;
COMPETE 2020 (POCI-01-0145-FEDER-006684), through national
funds and where applicable co-financed by the FEDER, within the
PT2020 Partnership Agreement; the Projects FoSynBio (POCI-01-0145-
FEDER-029549) and NewFood – Food Technologies Valorization
(NORTE-324 01-0246-FEDER-000043). The authors also acknowledge
BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by
the European Regional Development Fund under the scope of
Norte2020 -Programa Operacional Regional do Norte.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.lwt.2020.109322.
References
Adamberg, K., Adamberg, S., Ernits, K., Larionova, A., Voor, T., Jaagura, M., et al. (2018).
Composition and metabolism of fecal microbiota from normal and overweight chil-
dren are differentially affected by melibiose, raffinose and raffinose-derived fructans.
Anaerobe, 52, 100–110.
Adamberg, S., Sumeri, I., Uusna, R., Ambalam, P., Kondepudi, K. K., Adamberg, K., et al.
(2014). Survival and synergistic growth of mixed cultures of bifidobacteria and lac-
tobacilli combined with prebiotic oligosaccharides in a gastrointestinal tract simu-
lator. Microbial Ecology in Health and Disease, 25, 1–9.
Amabebe, E., & Anumba, D. O. C. (2018). The vaginal microenvironment: The physiologic
role of lactobacilli. Frontiers of Medicine, 5.
Amorim, C., Silvério, S. C., Cardoso, B. B., Alves, J. I., Pereira, M. A., & Rodrigues, L. R.
(2020). In vitro assessment of prebiotic properties of xylooligosaccharides produced
by Bacillus subtilis 3610 in a single-step process. Carbohydrate Polymers, 229, 115460.
Arantes, A. L., Alves, J. I., Alfons, J. M., Alves, M. M., & Sousa, D. Z. (2017). Enrichment
of syngas-converting communities from a multi-orifice baffled bioreactor. Microbial
Biotechnology, 11, 639–646.
Bothe, M., Maathuis, A., Bellmann, S., van der Vossen, J., Berressem, D., Koehler, A., et al.
(2017). Dose-dependent prebiotic effect of lactulose in a computer-controlled in vitro
model of the human large intestine. Nutrients, 9, 767.
Carlson, J. L., Erickson, J. M., Hess, J. M., Gould, T. J., & Slavin, J. L. (2017). Prebiotic
dietary fiber and gut health: Comparing the in vitro fermentations of beta-glucan,
inulin and xylooligosaccharide. Nutrients, 9, 1361.
Casanova, M. R., Azevedo-Silva, J., Rodrigues, L. R., & Preto, A. (2018). Colorectal cancer
cells increase the production of short chain fatty acids by Propionibacterium freu-
denreichii impacting on cancer cells survival. Frontiers in Nutrition, 5, 44.
Cummings, J. H., Macfarlane, G. T., & Englyst, H. N. (2001). Prebiotic digestion and
fermentation. American Journal of Clinical Nutrition, 73, 415s–420s.
Dahl, W. J., Hanifi, A., Zello, G. A., & Tyler, R. T. (2014). Gastrointestinal tolerance to
daily canned chickpea intake. Canadian Journal of Dietetic Practice and Research, 75,
218–221.
Das, K., Choudhary, R., & Thompson-Witrick, K. A. (2019). Effects of new technology on
the current manufacturing process of yogurt to increase the overall marketability of
yogurt. Lebensmittel-Wissenschaft und -Technologie- Food Science and Technology, 108,
69–80.
Date, Y., Nakanishi, Y., Fukuda, S., Nuijima, Y., Kato, T., Umehara, M., et al. (2014). In
vitro evaluation method for screening of candidate prebiotic foods. Food Chemistry,
152, 251–260.
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al.
(2005). Diversity of the human intestinal microbial flora. Science, 308, 1635–1638.
Fernando, W. M. U., Hill, J. E. G., Zello, A., Tyler, R. T., Dahl, W. J., & Van Kessel, A. G.
(2010). Diets supplemented with chickpea or its main oligosaccharide component
raffinose modify faecal microbial composition in healthy adults. Beneficial Microbes,
1, 197–207.
Ferro, S., Azevedo-Silva, J., Casal, M., Côrte-Real, M., Baltazar, F., & Preto, A. (2016).
Characterization of acetate transport in colorectal cancer cells and potential ther-
apeutic implications. Oncotarget, 7, 70639–70653.
Flint, H. J., Duncan, S. H., Scott, K. P., & Louis, P. (2015). Conference on ‘diet, gut mi-
crobiology and human health’ symposium 3: Diet and gut metabolism: Linking mi-
crobiota to beneficial products of fermentation links between diet, gut microbiota
composition and gut metabolism. Proceedings of the Nutrition Society, 74, 13–22.
Forbes (2015). Consumers want healthy foods-and will pay more for them. https://www.
forbes.com/sites/nancygagliardi/2015/02/18/consumers-want-healthy-foods-and-
will-pay-more-for-them/#24de393275c5, Accessed date: 31 January 2020.
Garrote, G. L., Abraham, A. G., & Rumbo, M. (2015). Is lactate an undervalued functional
component of fermented food products? Frontiers in Microbiology, 6.
Ghoddusi, H. B., Grandison, M. A., Grandison, A. S., & Tuohy, K. M. (2007). In vitro study
on gas generation and prebiotic effects of some carbohydrates and their mixtures.
Anaerobe, 13, 193–199.
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J.,
et al. (2017). The International Scientific Association for Probiotics and Prebiotics
(ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews
Gastroenterology & Hepatology, 14, 491–502.
Grand View Research (2018). Prebiotics market size, share & trends analysis by in-
gredients (fos, inulin, gos, mos), by application (food and beverages, dietary sup-
plements, animal feed), by region, and segment forecasts, 2014 – 2024. https://www.
grandviewresearch.com/industry-analysis/prebiotics-market, Accessed date: 31
January 2020.
Ito, Y., Moriwaki, H., Muto, Y., Kato, N., Watanabe, K., & Ueno, K. (1997). Effect of
lactulose on short-chain fatty acids and lactate production and on the growth-of
faecal flora, with special reference to Clostridium difficile. Journal of Medical
Microbiology, 46, 80–84.
Kang, D.-W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-
Means, S., et al. (2019). Long-term benefit of Microbiota Transfer Therapy on autism
symptoms and gut microbiota. Scientific Reports, 9.
Martínez-Villaluenga, C., Frías, J., Vidal-Valverde, C., & Gómez, R. (2005). Raffinose
family of oligosaccharides from lupin seeds as prebiotics: Application in dairy pro-
ducts. Journal of Food Protection, 68, 1246–1252.
Oliveira, C. S. F., Pereira, H., Alves, S., Castro, L., Baltazar, F., Chaves, S. R., et al. (2015).
Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through
autophagy-independent degradation of damaged mitochondria. Cell Death & Disease,
6, e1788.
Ose, R., Hirano, K., Maeno, S., Nakagawa, J., Salminen, S., Tochio, T., et al. (2018). The
ability of human intestinal anaerobes to metabolize different oligosaccharides: Novel
means for microbiota modulation? Anaerobe, 51, 110–119.
Pham, V. T., & Mohajeri, M. H. (2018). The application of in vitro human intestinal models
on the screening and development of pre- and probiotics. Beneficial Microbes, 9,
725–742.
Poeker, S. A., Geirnaert, A., Berchtold, L., Greppi, A., Krych, L., Steinert, R. E., et al.
(2018). Understanding the prebiotic potential of different dietary fibers using an in
vitro continuous adult fermentation model (PolyFermS). Scientific Reports, 8, 4318.
Rizzatti, G., Lopetuso, L. R., Gibiino, G., Binda, C., & Gasbarrini, A. (2017).
Proteobacteria: A common factor in human diseases. BioMed Research International,
1–7 ID 9351507.
Saad, N., Delattre, C., Urdaci, M., Schmitter, J. M., & Bressollier, P. (2013). An overview
of the last advances in probiotic and prebiotic field. Lebensmittel-Wissenschaft und
-Technologie- Food Science and Technology, 50, 1–16.
Salvador, A. F., Cavaleiro, A. J., Paulo, A. M. S., Silva, S. A., Guedes, A. P., Pereira, M. A.,
et al. (2019). Inhibition studies with 2-bromoethanesulfonate reveal a novel syn-
trophic relationship in anaerobic oleate degradation. Applied and Environmental
Microbiology, 85 e01733-18.
Samanta, A. K., Jayapal, N., Jayaram, C., Roy, S., Kolte, A. P., Senani, S., et al. (2015).
Xylooligosaccharides as prebiotics from agricultural by-products: Production and
applications. Bioactive Carbohydrates and Dietary Fibre, 5, 62–71.
Saremnezhad, S., Zargarchi, S., & Kalantari, Z. N. (2020). Calcium fortification of pre-
biotic ice-cream. Lebensmittel-Wissenschaft und -Technologie, 120, 108890.
Suarez, F. L., Springfield, J., Furne, J. K., Lohrmann, T. T., Kerr, P. S., & Levitt, M. D.
(1999). Gas production in humans ingesting a soybean flour derived from beans
naturally low in oligosaccharides. American Journal of Clinical Nutrition, 69, 135–139.
Tester, R. F., & Karkalas, J. (2003). Carbohydrates: Classification and properties. In B.
Caballero, L. Trugo, & P. M. Finglas (Eds.). Encyclopedia of food sciences and nutrition
(pp. 862–875). San Diego: Academic Press.
Topping, D. L., & Clifton, P. M. (2001). Short-chain fatty acids and human colonic
function: Roles of resistant starch and nonstarch polysaccharides. Physiological
Reviews, 81, 1031–1064.
C. Amorim, et al. LWT - Food Science and Technology 126 (2020) 109322
7
Tsitko, Wiik-Miettinen, Mattila, Rosa-Sibakov, Maukonen, Nordlund, & Saarela (2019). A
small in vitro fermentation model for screening the gut microbiota effects of different
fiber preparations. International Journal of Molecular Sciences, 20, 1925.
Visek, W. J. (1978). Diet and cell growth modulation by ammonia. American Journal of
Clinical Nutrition, 31, S216–S220.
WHO - World Health Organization (2018). Global report on diabetes. https://apps.who.
int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf.jsessionid=
AB2C916A6DBA6120F68D15F7A47BF5BC?sequence=1, Accessed date: 31 January
2020.
Yeung, A. W. K., Mocan, A., & Atanasov, A. G. (2018). Let food be thy medicine and
medicine be thy food: A bibliometric analysis of the most cited papers focusing on
nutraceuticals and functional foods. Food Chemistry, 269, 455–465.
Zhao, C., Wu, Y., Liu, X., Liu, B., Cao, H., Yu, H., et al. (2017). Functional properties,
structural studies and chemo-enzymatic synthesis of oligosaccharides. Trends in Food
Science & Technology, 66, 135–145.
C. Amorim, et al. LWT - Food Science and Technology 126 (2020) 109322
8
